Related Experiment Videos
Subcutaneous sumatriptan during the migraine aura. Sumatriptan Aura Study Group
1Department of Neurology, Royal Victoria Infirmary, Newcastle-upon-Tyne, UK.
Neurology
|September 1, 1994
Summary
Subcutaneous sumatriptan administered during migraine aura did not alter aura symptoms or prevent headache development. This migraine treatment study found no significant difference between sumatriptan and placebo in headache onset or aura duration.
Area of Science:
- Neurology
- Clinical Pharmacology
Background:
- Migraine aura represents a neurological phenomenon preceding headache onset.
- Early intervention during migraine aura is a potential therapeutic strategy.
Purpose of the Study:
- To evaluate the efficacy of subcutaneous sumatriptan administered during migraine aura.
- To determine if sumatriptan affects aura duration, characteristics, or subsequent headache development.
Main Methods:
- Double-blind, placebo-controlled, multicenter, parallel-group study.
- 171 patients with typical migraine aura self-injected with either 6 mg sumatriptan or placebo.
- Assessed aura duration, symptom profile, and headache incidence within 6 hours.
Main Results:
- Median aura duration was similar: 25 minutes (sumatriptan) vs. 30 minutes (placebo).
- Aura symptom profiles did not differ significantly between groups.
- Headache development was comparable: 68% (sumatriptan) vs. 75% (placebo).
Conclusions:
- Subcutaneous sumatriptan administered during migraine aura does not prolong or modify the aura.
- Sumatriptan did not prevent or significantly delay the onset of migraine headache in this study.